Location History:
- Scarsdale, NJ (US) (2021)
- Chicago, IL (US) (2016 - 2023)
- Scarsdale, NY (US) (2019 - 2024)
Company Filing History:
5 out of 4,447 
4 out of 560 
3 out of 56 
Years Active: 2016-2025
Title: **Yang Shen: Innovator in Multispecific Binding Molecules**
Introduction
Yang Shen, an accomplished inventor based in Scarsdale, NY, has made significant contributions to the field of biotechnology. With an impressive portfolio of seven patents, his work primarily focuses on advancing treatments for cancer through innovative binding molecules. His dedication to research and innovation is evident in his recent patents, demonstrating his commitment to improving patient outcomes.
Latest Patents
Yang Shen’s latest patents revolve around N-terminal scFv multispecific binding molecules (MBMs). These innovative compounds comprise an N-terminal scFv combined with a first Fab and a second Fab. Shen’s patents describe MBM conjugates that include cytotoxic or cytostatic agents, as well as pharmaceutical compositions containing both the MBMs and these conjugates. Moreover, he has outlined methods for using these MBMs, MBM conjugates, and pharmaceutical compositions specifically for cancer treatment. His research also delves into nucleic acids encoding the MBMs and cells engineered to express them. The methods of producing these MBMs represent a significant advancement in the field.
Career Highlights
Throughout his career, Yang Shen has worked with reputable organizations such as Eli Lilly and Company and Zymeworks Inc. His professional experience with these leading companies underscores his role as a key player in the pharmaceutical and biotechnology sectors. By combining his expertise and passion for innovation, he has successfully developed groundbreaking therapies for pressing medical challenges.
Collaborations
Yang has collaborated with several talented individuals in the industry, including coworkers Yiwen Li and Yi Zhang. These collaborations have fostered a creative environment conducive to developing innovative solutions in therapeutic technologies. Working alongside fellow experts, Shen has been able to leverage diverse skill sets to drive advancements in cancer treatment options.
Conclusion
In summary, Yang Shen’s inventive spirit and dedication to his work have resulted in multiple patents that stand as a testament to his ingenuity in the field of biotechnology. His ongoing research in multispecific binding molecules holds promise for the future of cancer therapies. As he continues to innovate and collaborate with others, Yang Shen remains a significant figure in the advancement of medical science and technology.